GLP-1 receptor agonists provide important cardiometabolic benefits, particularly for weight management, glycemic control, renal protection, and reduction of atherosclerotic cardiovascular risk, although their direct effects in established heart failure remain less certain
Baseline evaluation should include HbA1c (if diabetic), comprehensive metabolic panel, lipid profile, and assessment for contraindications
NOTE: Concentration is lot-dependent and can vary from 0.85-1.15 mg/mL GCG is also known as GLP1, or Glucagon
Evidence snapshot: The article cites a 2025 randomized, placebo-controlled trial (reduced cravings and heavy drinking), a 2024 real-world cohort (lower AUD risk with semaglutide), and expert reviews calling the data promising but preliminary